A new study published in the journal of Public Library of Science found that the triglyceride levels of individuals with ...

This study highlights the efficacy of home-based tDCS in treating major depressive disorder, with significant improvements in ...

The app, called Rejoyn, is cleared as a supplement to currently approved therapies and works by using specifically designed ...

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the ...

In a recent study published in Nature, researchers used advanced brain imaging techniques to explore how certain brain networks differ in people with depression. They discovered that a specific brain ...

Mirtazapine is an FDA- approved, prescription-only medication for major depressive disorder in adults. The medication works by increasing certain hormones in the brain to improve mood. Whichever ...

A new Macquarie University study suggests that instead of relying on the 'bible' of mental health diagnosis, we need a ...

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel ...

New research underscores the role of the immune system in depression, linking inflammation to poor response to standard antidepressants and highlighting the importance of personalized medicine in ...

About the SPN-820 Phase 2a Clinical Study The study is a Phase 2a open-label study in 40 subjects with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, ...

Cybin secures a U.S. patent for its CYB005 program targeting CNS disorders and prepares to launch a Phase 3 trial for CYB003 in major depressive disorder.

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...